Updated:
BioVie Inc.
BioVie develops investigational therapies for neurological disorders and advanced liver disease. Review its business and dated financial history.
Overview
BioVie is a clinical-stage company developing investigational therapies for neurological and neurodegenerative disorders and advanced liver disease. Its research includes bezisterim, formerly known as NE3107; the candidate remains investigational. On September 11, 2026, BioVie entered an at-the-market stock-offering arrangement that permitted sales from time to time without requiring them. That agreement provided financing capacity rather than establishing that the full amount had been raised. Its reported principal executive office is in Carson City, NV (United States). For fiscal 2026, ended 2026-06-30, its originally reported results included a net loss of USD 22,072,863; cash used in operations of USD 19,024,806. At that year-end, it reported total assets of USD 14,250,462 and cash and cash equivalents of USD 8,977,370.
Company overview
- Legal name
- BIOVIE INC.
- Former names in filing history
- NANOANTIBIOTICS, INC. (2013-07-02 to 2016-07-22)
- Classification
- Public company
- Industry (SIC)
- 2834 — Pharmaceutical Preparations
- Headquarters
- Carson City, NV, United States
- Incorporated in
- NV
- Fiscal year end
- June 30
- SEC CIK
- 0001580149
Financials
Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.
| Fiscal year | Period end | Net income | Total assets | Cash and equivalents | Operating cash flow |
|---|---|---|---|---|---|
| FY2026USD | -$22.1M | $14.3M | $9.0M | -$19.0M | |
| FY2025USD | -$17.5M | $21.6M | $17.5M | -$19.0M | |
| FY2024USD | -$32.1M | $25.2M | $23.8M | -$27.9M | |
| FY2023USD | -$50.3M | $35.1M | $19.5M | -$40.3M |
Recent SEC filings
| Form | Filed | Period | Filing |
|---|---|---|---|
| DEF 14A | DEF 14A | ||
| 8-K | CURRENT REPORT | ||
| 10-K | FORM 10-K FOR PERIOD ENDED JUNE 30, 2026 | ||
| 8-K | CURRENT REPORT | ||
| S-1 | — | FORM S-1 REGISTRATION STATEMENT | |
| 10-Q | FORM 10-Q FOR PERIOD ENDING MARCH 31, 2026 | ||
| 10-Q | FORM 10-Q FOR PERIOD ENDING DECEMBER 31, 2025 | ||
| 8-K | CURRENT REPORT | ||
| 8-K | CURRENT REPORT | ||
| 10-Q | FORM 10-Q FOR PERIOD ENDING SEPTEMBER 30, 2025 | ||
| DEF 14A | DEF 14A | ||
| 10-K | FORM 10-K |
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Research BioVie Inc. in Altss
Track this company’s investors, transactions and relationships in Altss.